Your browser doesn't support javascript.
loading
Identifying metabolic features of colorectal cancer liability using Mendelian randomization.
Bull, Caroline J; Hazelwood, Emma; Bell, Joshua A; Tan, Vanessa Y; Constantinescu, Andrei-Emil; Borges, Maria Carolina; Legge, Danny N; Burrows, Kimberly; Huyghe, Jeroen R; Brenner, Hermann; Castellví-Bel, Sergi; Chan, Andrew T; Kweon, Sun-Seog; Marchand, Loic Le; Li, Li; Cheng, Iona; Pai, Rish K; Figueiredo, Jane C; Murphy, Neil; Gunter, Marc J; Timpson, Nicholas J; Vincent, Emma E.
Afiliação
  • Bull CJ; MRC Integrative Epidemiology Unit at the University of Bristol, Bristol, UK.
  • Hazelwood E; Population Health Sciences, Bristol Medical School, University of Bristol, Bristol, UK.
  • Bell JA; Translational Health Sciences, Bristol Medical School, University of Bristol, UK.
  • Tan VY; MRC Integrative Epidemiology Unit at the University of Bristol, Bristol, UK.
  • Constantinescu AE; Population Health Sciences, Bristol Medical School, University of Bristol, Bristol, UK.
  • Borges MC; MRC Integrative Epidemiology Unit at the University of Bristol, Bristol, UK.
  • Legge DN; Population Health Sciences, Bristol Medical School, University of Bristol, Bristol, UK.
  • Burrows K; MRC Integrative Epidemiology Unit at the University of Bristol, Bristol, UK.
  • Huyghe JR; Population Health Sciences, Bristol Medical School, University of Bristol, Bristol, UK.
  • Brenner H; MRC Integrative Epidemiology Unit at the University of Bristol, Bristol, UK.
  • Castellví-Bel S; Population Health Sciences, Bristol Medical School, University of Bristol, Bristol, UK.
  • Chan AT; MRC Integrative Epidemiology Unit at the University of Bristol, Bristol, UK.
  • Kweon SS; Population Health Sciences, Bristol Medical School, University of Bristol, Bristol, UK.
  • Marchand LL; Translational Health Sciences, Bristol Medical School, University of Bristol, UK.
  • Li L; MRC Integrative Epidemiology Unit at the University of Bristol, Bristol, UK.
  • Cheng I; Population Health Sciences, Bristol Medical School, University of Bristol, Bristol, UK.
  • Pai RK; Public Health Sciences Division, Fred Hutchinson Cancer Center, Seattle, Washington, USA.
  • Figueiredo JC; Division of Clinical Epidemiology and Aging Research, German Cancer Research Center (DKFZ), Heidelberg, Germany.
  • Murphy N; Division of Preventive Oncology, German Cancer Research Center (DKFZ) and National Center for Tumor Diseases (NCT), Heidelberg, Germany.
  • Gunter MJ; German Cancer Consortium (DKTK), German Cancer Research Center (DKFZ), Heidelberg, Germany.
  • Timpson NJ; Gastroenterology Department, Hospital Clínic, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBEREHD), University of Barcelona, Barcelona, Spain.
  • Vincent EE; Division of Gastroenterology, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, USA.
medRxiv ; 2023 Nov 09.
Article em En | MEDLINE | ID: mdl-36945480
Background: Recognizing the early signs of cancer risk is vital for informing prevention, early detection, and survival. Methods: To investigate whether changes in circulating metabolites characterise the early stages of colorectal cancer (CRC) development, we examined associations between a genetic risk score (GRS) associated with CRC liability (72 single nucleotide polymorphisms) and 231 circulating metabolites measured by nuclear magnetic resonance spectroscopy in the Avon Longitudinal Study of Parents and Children (N=6,221). Linear regression models were applied to examine associations between genetic liability to colorectal cancer and circulating metabolites measured in the same individuals at age 8, 16, 18 and 25 years. Results: The GRS for CRC was associated with up to 28% of the circulating metabolites at FDR-P<0.05 across all time points, particularly with higher fatty acids and very-low- and low-density lipoprotein subclass lipids. Two-sample reverse Mendelian randomization (MR) analyses investigating CRC liability (52,775 cases, 45,940 controls) and metabolites measured in a random subset of UK Biobank participants (N=118,466, median age 58y) revealed broadly consistent effect estimates with the GRS analysis. In conventional (forward) MR analyses, genetically predicted polyunsaturated fatty acid concentrations were most strongly associated with higher CRC risk. Conclusions: These analyses suggest that higher genetic liability to CRC can cause early alterations in systemic metabolism, and suggest that fatty acids may play an important role in CRC development. Funding: This work was supported by the Elizabeth Blackwell Institute for Health Research, University of Bristol, the Wellcome Trust, the Medical Research Council, Diabetes UK, the University of Bristol NIHR Biomedical Research Centre, and Cancer Research UK. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. This work used the computational facilities of the Advanced Computing Research Centre, University of Bristol - http://www.bristol.ac.uk/acrc/.
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Clinical_trials / Observational_studies / Prognostic_studies / Risk_factors_studies / Screening_studies Idioma: En Revista: MedRxiv Ano de publicação: 2023 Tipo de documento: Article País de publicação: Estados Unidos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Clinical_trials / Observational_studies / Prognostic_studies / Risk_factors_studies / Screening_studies Idioma: En Revista: MedRxiv Ano de publicação: 2023 Tipo de documento: Article País de publicação: Estados Unidos